Company Summary

Shire Pharmaceutical Holdings Ireland Limited was set up on Thursday the 15th of May 2008. Their current address is 5 Riverwalk,Citywest Business Campus,Dublin 24, and the company status is Normal. The company's current directors Adele Deering, Sean Brennan, Vincent Dunne, Fearghas MacGilp Kerr Carruthers and Michael Thomas Garry have been the director of 23 other Irish companies between them; 3 of which are now closed. Shire Pharmaceutical Holdings Ireland Limited has 1 shareholder. This Irish company shares its Eircode with at least 23 other companies.

Company Name:Shire Pharmaceutical Holdings Ireland Limited
Company Status:NORMAL
Company Address:5 Riverwalk,
Citywest Business Campus,
Dublin 24
Telephone:+353 (0)1 617 3490200
Key Executive:Michael Thomas Garry
Company Size:Log-In To View

Key Contact Profile

Michael Thomas Garry is a Company Director of Shire Pharmaceutical Holdings Ireland Limited since 2008 and a listed Director of 11 other companies.

Generate a B2B Marketing List with ease and grow your business. Identify key decision makers and pre-qualified new prospects for your sales and business development teams.

Similar Companies - Create a marketing list of similar companies

Latest Updates

The latest documents filed with the Companies Registration Office for Shire Pharmaceutical Holdings Ireland Limited (which can include the Account Details) are listed below.

CRO DocumentEffective DateReceived By CROView Now
N1 CONVERSION TO LTD21/11/201629/11/2016Join Up
CONSTITUTION21/11/201629/11/2016Join Up
SPECIAL RESOLUTION21/11/201629/11/2016Join Up
CERTIFICATE21/11/201629/11/2016Join Up
B1 ANNUAL RETURN30/09/201628/10/2016Join Up

View CRO company documents and company reports any Irish company or business with ease.

Credit Report

View the Latest Credit Report and Credit Limit on Shire Pharmaceutical Holdings Ireland Limited.

Company Status:Normal
Latest Credit Movement:
Date of Last Movement:29/12/2016
Latest Accounts Filed:28/10/2016
Report Based on Accounts:31/12/2015
Next Set of Accounts Due:30/09/2017
Credit Score:Join-Up to View

Full Credit Rating

To View the latest Credit Rating or Credit Limit on Shire Pharmaceutical Holdings Ireland Limited simply click 'Log-In' or 'Join-Up' below.

Vision-net Credit Scores save your business the time and cost of chasing slow payers. Evaluate risk at client application stage or run continuous credit checks on your full customer base.


Satisfy due diligence requirments on Shire Pharmaceutical Holdings Ireland Limited in one single 'time-saving' search. Run full background checks for Fitness and Probity on the directors of Shire Pharmaceutical Holdings Ireland Limited and Anti-Money Laundering checks (AML checks) on Shire Pharmaceutical Holdings Ireland Limited

Director:Michael Thomas Garry
Director:Vincent Dunne
Other Directors:Shire Pharmaceutical Holdings Ireland Limited has 3 other Directors.

Ownership Structure

Company Type:LTD - Private Company Limited By Shares
Number of Shareholders:1


Log-in now to run Due Diligence checks and Compliance checks on Shire Pharmaceutical Holdings Ireland Limited or click Join-up to get started.

Background check Companies, Sole Traders or Individuals and minimise your spend with more efficient Anti-Money Laundering checks and reports.

Ask Us A Question...?

Is Your Organisation PEP ready?


The new 4th Directive on AML is effective this June 2017. Identify PEPs in your customer base faster and easier with our AML solution.

Read More »

Monitoring Alerts 101: Staying A Step Ahead


The Vision-net alerts service is one of the most comprehensive on the market. It takes the cost and time out of monitoring the companies that are important to your business.

Read More »

Company Start-Ups remain strong with a 19% increase this January


A review of the new Irish companies formed this January and the industry sector's they chose to set up in.

Read More »

The 2017 Annual Review


We are in acceleration mode and Ireland has taken its place as Europe's fastest growing economy. Many aspects of that recovery are demonstrated in our 2017 Annual Review.

Read More »